Rituximab – USA

Rituximab – USA

On Dec. 16, 2020, Federal Circuit affirmed (Rule 36 judgment) PTAB finding method of use patent invalid as obvious. You can find the IPR details reported here on this blog.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved